# A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

> **NCT02312050** · PHASE2 · UNKNOWN · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 375 (estimated)

## Conditions studied

- Diabetic Chronic Kidney Disease

## Interventions

- **DRUG:** GCS-100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02312050
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2015-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312050, "A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02312050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*